Skeletal effects of parathyroid hormone (1-34) in ovariectomized rats with or without concurrent administration of salmon calcitonin

AAPS PharmSci

Volumn 3, Issue 4, 2001, Pages

  DeLuca, Patrick P ^b   Dani, Bhas A ^a  

^a NEKTAR THERAPEUTICS   (United States)

^b University of Kentucky   (United States)

Author keywords

Cancellous bone; Hormone (1 34); Human parathyroid; Infusion; Ovariectomized rate; Salmon calcitonin; Volume

Indexed keywords

DRUG VEHICLE; PARATHYROID HORMONE; SALCATONIN; ANALGESIC AGENT; CALCITONIN; PARATHYROID HORMONE (1 34); PARATHYROID HORMONE (1-34); PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; BONE MINERAL; CANCELLOUS BONE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INFUSION; FEMALE; METAPHYSIS; MORPHOMETRICS; NONHUMAN; OSMOTIC PUMP; OSTEOLYSIS; OVARIECTOMY; RAT; RAT STRAIN; TIBIA; ANIMAL; BLOOD; BONE; COMPARATIVE STUDY; DRUG SCREENING; HISTOLOGY; INFUSION PUMP; INTRAVENOUS DRUG ADMINISTRATION; OSMOSIS; SPRAGUE DAWLEY RAT;

ANALGESICS; ANIMALS; BONE AND BONES; BONE DENSITY; CALCITONIN; DRUG EVALUATION, PRECLINICAL; FEMALE; INFUSION PUMPS, IMPLANTABLE; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; OSMOSIS; OVARIECTOMY; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TIBIA;

EID: 0035783396     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993;14:690-709.
2. Lindsay R, Nieves J, Formica C, et al. Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350:550-555.
3. Morley R, Whitfield JF, Willick GE. Anabolic effects of parathyroid hormone on bone. Trends Endocrinol Metab. 1997;8:225-231.
4. Reeve J. PTH: a future role in the management of osteoporosis? J Bone Miner Res. 1996;11:440-445.
5. Whitfield JF, Morley P. Anabolic treatments for osteoporosis. Boca Raton: CRC Press; 1998.
6. Dobnig H, Turner R. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997;138:4607-4612.
7. Tam CS, Heersche JNM, Murray TM, Parsons JA. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology. 1982;110:506-512.
8. Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to PTH. J Bone Miner Res. 1992;7:65-72.
9. Uzawa T, Hori M, Ejiri S, Ozawa H. Comparison of the effects of intermittent and continuous administration of human parathyroid hormone (1-34) on rat bone. Bone. 1995;16:477-484.
10. Kitazawa R, Imai Y, Fukase M, Fujita T. Effects of continuous infusion of PTH and PTH-related peptide on rat bone in vivo: comparative study of histomorphometry. Bone Miner. 1991;12:157-166.
11. Wronski TJ, Walsh CC, Ignaszewski LA. Histologic evidence for osteopenia and increased bone turnover in ovariectomized rats. Bone. 1986;7:119-123.
12. Turner RT, Wakley GK, Hannon KS, Bell NH. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovariectomized hormone-deficient rats. Endocrinology. 1988;122:1146-1150.
13. Wronski TJ, Cintron M, Dann LM. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif Tissue Int. 1988;43:179-183.
14. Rixon RH, Whitfield JF, Gagnon L, et al. Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase. J Bone Miner Res. 1994;9:1179-1189.
15. Whitfield JF, Morley P, Willick GE, et al. Stimulation of growth of femoral trabecular bone in ovariectomized rats by the novel parathyroid hormone fragment, hPTH (1-31)NH2 (Ostabolin). Calcif Tissue Int. 1996;58:81-87.
16. Heany RP, Recker RR, Saville PD. Menopausal changes in bone remodeling. J Lab Clin Med. 1978;92:964-970.
17. Delmas PD, Wahner HW, Mann KG, Riggs BL. Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone gla-protein. J Lab Clin Med. 1983;102:470-476.
18. Riis BJ, Rodbro P, Christiansen C. The role of serum concentrations of sex steroids and bone turnover in the development and occurrence of postmenopausal osteoporosis. Calcif Tissue Int. 1986;38:318-322.
19. Stepan JJ, Pospichal J, Presl J, Pacovsky V. Bone loss and biochemical indices of remodeling in surgically induced postmenopausal women. Bone. 1987;8:279-284.
20. Kalu DN, Liu CC, Hardin RR, Hollis BW. The aged model of ovarian hormone deficiency bone loss. Endocrinology. 1989;124:7-16.
21. Thompson DD, Simmons HA, Pirie CM, Ze HZ. FDA guidelines and animal models for osteoporosis. Bone. 1995;16:157-161.
22. Morley P, Whitfield JF, Willick GE, et al. Prolonged low-dose infusion of human parathyroid hormone does not increase femoral cancellous bone volume in ovariectomized rats. Eur J Endocrinol. 1999;141:70-74.
23. Shen V, Birchman R, Wu DD, Lindsay R. Skeletal effects of parathyroid infusion in ovariectomized rats with or without estrogen repletion. J Bone Miner Res. 2000;15:740-746.
24. Zhou H, Shen V, Dempster DW, Lindsay R. Continuous parathyroid hormone and estrogen administration increase vertebral cancellous bone volume and cortical width in the estrogen-deficient rat. J Bone Miner Res. 2001;16:1300-1307.
25. Li M, Shen Y, Burton KW, et al. A comparison of the skeletal effects of intermittent and continuous administration of calcitonin in ovariectomized rats. Bone. 1996;18(4):375-380.
26. Wronski TJ, Yen CF, Burton KW, et al. Skeletal effects of calcitonin in ovariectomized rats. Endocrinology. 1991;129:2246-2250.
27. Wronski TJ, Schenck PA, Cintron M, Walsh CC. Effect of body weight on osteopenia in ovariectomized rats. Calcif Tissue Int. 1987;40:155-159.
28. Gaggi R, Beltrandi E, Dall'Ollio R, Ferri S. Relationships between hypocalcemic and anorectic effect of calcitonin. Pharmacol Res Commun. 1985;17:209-215
29. Yates AJ, Gutierrez GE, Garrett IR, et al. A noncyclical analog of salmon calcitonin (N-propionyl di-ala1,7 des-leu19 sCT) retains full potency without inducing anorexia in rats. Endocrinology. 1990;126:2845-2849.